Mouse behavioural analysis in systems biology

P Van Meer, J Raber - Biochemical Journal, 2005 - portlandpress.com
Molecular techniques allowing in vivo modulation of gene expression have provided unique
opportunities and challenges for behavioural studies aimed at understanding the function of …

Bacterial contamination in platelet concentrates

…, A Berzuini, D Prati, M Satake, D Korte, PF Meer… - Vox sanguinis, 2014 - infona.pl
… Georgsen, P. Morel, C. Naegelen, L. … P. Cazenave, J. Dreier, T. … de Korte, PF van der
Meer, JL Kerkhoffs, L. Blanco, J. Kjeldsen‐Kragh, A.‐…

[HTML][HTML] Levelling the translational gap for animal to human efficacy data

…, WPC Boon, EHM Moors, PJK van Meer - Animals, 2020 - mdpi.com
Simple Summary The value of animal research has been increasingly debated, owing to
high failure rates in drug development. A potential contributor to this situation is the lack of …

Compression guidelines for diagnostic telepathology

DJ Foran, PP Meer, T Papathomas… - IEEE Transactions on …, 1997 - ieeexplore.ieee.org
As the healthcare community has begun to rely increasingly upon digital technologies for
acquisition, storage, and transmission of pictorial data, image compression has become an …

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

PJK Van Meer, M Kooijman, V Brinks… - MAbs, 2013 - Taylor & Francis
The immunogenicity of biopharmaceuticals used in clinical practice remains an unsolved
challenge in drug development. Non-human primates (NHPs) are often the only relevant …

The ability of animal studies to detect serious post marketing adverse events is limited

PJK van Meer, M Kooijman, CC Gispen-de Wied… - Regulatory Toxicology …, 2012 - Elsevier
The value of animal studies to assess drug safety is unclear because many such studies are
biased and have methodological shortcomings. We studied whether post-marketing serious …

[HTML][HTML] A standardised framework to identify optimal animal models for efficacy assessment in drug development

…, CC Gispen-de Wied, H Schellekens, PJK van Meer - PLoS …, 2019 - journals.plos.org
Introduction Poor translation of efficacy data derived from animal models can lead to clinical
trials unlikely to benefit patients–or even put them at risk–and is a potential contributor to …

[HTML][HTML] Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease

…, GS Ferreira, PJK van Meer… - European journal of …, 2019 - Elsevier
Clinical trial failures (>99%) in Alzheimer's disease are in stark contrast to positive efficacy
data in animals. We evaluated the correlation between animal and clinical efficacy outcomes (…

The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals

PJK Van Meer, ML Graham, HJ Schuurman - European journal of …, 2015 - Elsevier
Nonclinical studies in animals are conducted to demonstrate proof-of-concept, mechanism of
action and safety of new drugs. For a large part, in particular safety assessment, studies are …

Land consolidation through land fragmentation: case studies from Taiwan

PV Meer - Land Economics, 1975 - JSTOR
Land property rights take many forms, of which individual and joint ownership are only two.
Individual ownership means that one person owns each cadastral plot. Joint ownership …